Literature DB >> 31933912

Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein.

Yanping Wang1, Ying Liang2.   

Abstract

BACKGROUND: There was limited data concerning predicting ability of calprotectin for disease activity of rheumatoid arthritis (RA) patients with normal C-reactive protein (CRP) level. This study was conducted to evaluate serum calprotectin levels in active RA patients and analyze its predicting value for disease activity evaluation despite normal CRP level.
METHODS: A total of 162 patients with active RA patients with normal CRP levels and 57 healthy subjects were enrolled. Serum calprotectin was measured by using a commercially available enzyme-linked immunosorbent assay (ELISA), and baseline clinical characteristics were collected. The DAS-28 scores were evaluated as indictors of disease activity. The predicting value of calprotectin in disease activity of RA patients with normal CPR was analyzed by using univariate and multivariate analysis and receiver operating characteristic curve.
RESULTS: Serum levels of calprotectin of patients with active RA were significantly higher than that of the healthy controls (3.5±3.2 vs. 2.5±0.8, P<0.01). Univariate analysis showed that serum calprotectin levels were significantly associated with the disease activity of RA. The mean serum calprotectin levels of patients with a high disease activity (DAS-28>5.1) was significantly higher than that of RA patients with low-moderate disease activity (4.3±3.5 vs. 2.6±1.1, P<0.01). Serum calprotectin levels also was evaluated as an independent predictive factor for disease activity of RA in multivariate analysis (OR, 2.31; 95% CI, 1.12-6.84; P<0.01).
CONCLUSIONS: Serum calprotectin levels can be used as a promising indictor for disease activity in active RA patients while CRP fails to do so. IJCEP
Copyright © 2019.

Entities:  

Keywords:  C-reactive protein; Rheumatoid arthritis; calprotectin; disease activity

Year:  2019        PMID: 31933912      PMCID: PMC6945154     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  One year in review 2017: pathogenesis of rheumatoid arthritis.

Authors:  Francesca Angelotti; Alice Parma; Giacomo Cafaro; Riccardo Capecchi; Alessia Alunno; Ilaria Puxeddu
Journal:  Clin Exp Rheumatol       Date:  2017-06-07       Impact factor: 4.473

2.  Changes in anti-citrullinated protein antibody isotype levels in relation to disease activity and response to treatment in early rheumatoid arthritis.

Authors:  A Kastbom; K Roos Ljungberg; M Ziegelasch; J Wetterö; T Skogh; K Martinsson
Journal:  Clin Exp Immunol       Date:  2018-10-14       Impact factor: 4.330

3.  The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness.

Authors:  F Wolfe; T Pincus
Journal:  J Rheumatol       Date:  2001-08       Impact factor: 4.666

4.  The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis.

Authors:  H B Berntzen; U Olmez; M K Fagerhol; E Munthe
Journal:  Scand J Rheumatol       Date:  1991       Impact factor: 3.641

5.  Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases.

Authors:  J G Brun; R Jonsson; H J Haga
Journal:  J Rheumatol       Date:  1994-04       Impact factor: 4.666

6.  Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity.

Authors:  J G Brun; H J Haga; E Bøe; I Kallay; C Lekven; H B Berntzen; M K Fagerhol
Journal:  J Rheumatol       Date:  1992-06       Impact factor: 4.666

7.  Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.

Authors:  José Inciarte-Mundo; Virginia Ruiz-Esquide; Maria Victoria Hernández; Juan D Cañete; Sonia Raquel Cabrera-Villalba; Julio Ramirez; Jordi Yagüe; Raimon Sanmarti
Journal:  Rheumatology (Oxford)       Date:  2015-08-04       Impact factor: 7.580

8.  Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab.

Authors:  Gokhan Sargin; Taskin Senturk; Irfan Yavasoglu; Reyhan Kose
Journal:  Int J Rheum Dis       Date:  2018-10-18       Impact factor: 2.454

9.  Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.

Authors:  Lucie Andrés Cerezo; Heřman Mann; Ondřej Pecha; Lenka Pleštilová; Karel Pavelka; Jiří Vencovský; Ladislav Senolt
Journal:  Arthritis Res Ther       Date:  2011-07-26       Impact factor: 5.156

10.  The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis.

Authors:  Katsue Sunahori; Masahiro Yamamura; Jiro Yamana; Kouji Takasugi; Masanori Kawashima; Hiroshi Yamamoto; Walter J Chazin; Yuichi Nakatani; Satoru Yui; Hirofumi Makino
Journal:  Arthritis Res Ther       Date:  2006-04-13       Impact factor: 5.156

View more
  7 in total

1.  Analysis of Xinjiang HPV16 L1 gene polymorphisms: a newly developed, low-cost enzyme-linked immunosorbent assay.

Authors:  Zhe Wang; Yan Tang; Hongwei Dang; Xuxuan Zhang; Lijuan Pang; Pengyan Wang; Chuangfu Chen; Yan Ren
Journal:  Int J Clin Exp Pathol       Date:  2022-01-15

2.  Circulating Calprotectin as a Biomarker of COVID-19 Severity.

Authors:  Michael Mahler; Pier-Luigi Meroni; Maria Infantino; Katherine A Buhler; Marvin J Fritzler
Journal:  Expert Rev Clin Immunol       Date:  2021-04-13       Impact factor: 4.473

3.  Serum and Fecal Markers of Intestinal Inflammation and Intestinal Barrier Permeability Are Elevated in Parkinson's Disease.

Authors:  Laura Dumitrescu; Daciana Marta; Adela Dănău; Antonia Lefter; Delia Tulbă; Liviu Cozma; Emilia Manole; Mihaela Gherghiceanu; Laura Cristina Ceafalan; Bogdan Ovidiu Popescu
Journal:  Front Neurosci       Date:  2021-06-18       Impact factor: 4.677

4.  Serum Calprotectin is Indicating Clinical and Ultrasonographic Disease Activity in Rheumatoid Arthritis, even with Normal C-Reactive Protein Levels.

Authors:  Murat Torgutalp; Mucteba Enes Yayla; Didem Sahin Eroglu; Ayse Bahar Kelesoglu Dincer; Emine Uslu Yurteri; Ilyas Ercan Okatan; Serdar Sezer; Emine Gozde Aydemir Guloksuz; Ebru Us; Tahsin Murat Turgay; Gulay Kinikli; Askin Ates
Journal:  Mediterr J Rheumatol       Date:  2021-02-15

5.  Synovial calprotectin for the diagnosis of periprosthetic joint infection: a diagnostic meta-analysis.

Authors:  Xinyu Peng; Haitao Zhang; Pengfei Xin; Guowen Bai; Yingjie Ge; Miaoxin Cai; Rui Wang; Yueguang Fan; Zhihui Pang
Journal:  J Orthop Surg Res       Date:  2022-01-04       Impact factor: 2.359

6.  Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.

Authors:  Matthias Jarlborg; Delphine S Courvoisier; Céline Lamacchia; Laura Martinez Prat; Michael Mahler; Chelsea Bentow; Axel Finckh; Cem Gabay; Michael J Nissen
Journal:  Arthritis Res Ther       Date:  2020-05-06       Impact factor: 5.156

7.  Sex differences in the association between self-rated health and high-sensitivity C-reactive protein levels in Koreans: a cross-sectional study using data from the Korea National Health and Nutrition Examination Survey.

Authors:  Se-Won Park; Seong-Sik Park; Eun-Jung Kim; Won-Suk Sung; In-Hyuk Ha; Boyoung Jung
Journal:  Health Qual Life Outcomes       Date:  2020-10-14       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.